William Blair reduced their FY2024 EPS estimates for shares of AbbVie in a research note issued on Tuesday, January 21st.

Buying $1000 In ABBV: If an investor had bought $1000 of ABBV stock 5 years ago, it would be worth $2,026.90 today based on a ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...

Research analysts at William Blair decreased their FY2025 earnings per share (EPS) estimates for shares of AbbVie in a note ...

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target ...

AbbVie will commit less capital towards experimental medicines for psychiatric disease, CEO Robert Michael said at an ...

AbbVie (ABBV) and Neomorph announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple ...